Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.

Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.

Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.

Matching Placebo for PF-06865571 for each cohort.